General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General discussions related to Multi-Cancer Early Detection technology
HR 7085: BIOSECURE Act; all provisions
General Discussion related to funding for National Institutes of Health
General Discussion related to funding for Centers for Disease Control and Prevention
General Discussion related to funding for biosurveillance
General Discussions related to the implementation of P.L. 117-167 (HR 4346): Chips and Science Act
General Discussions related to export control and trade policy
General Discussions related to biotechnology and genomics education
P.L. 118-31 (H.R. 2670): National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
Duration: January 1, 2018
to
March 31, 2021
General Issues: Health Issues , Trade (Domestic & Foreign) , Defense , Government Issues , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Veterans , Budget/Appropriations
Spending: about $12,410,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: House of Representatives, U.S. Senate, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), Defense - Dept of (DOD), State - Dept of (DOS), Office of Science & Technology Policy (OSTP), Natl Science Foundation (NSF), Natl Security Council (NSC), U.S. Trade Representative (USTR), White House Office, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Kathleen Lynch None
NONE
ROBERT MCMILLIN 12/2012 - 7/2013 - FIELD REPRESENTATIVE-SEN. SAXBY CHAMBLISS; 7/2013 - 12/2014 - COUNSEL-SEN. SAXBY CHAMBLISS; 1/2015 - 11/2015 - COUNSEL & 11/2015 - 5/2019 GENERAL COUNSEL - SENATE COMM. ON HEALTH, EDUCATION, LABOR, & PENSIONS
[CONTACTS RE: HR 4144 ONLY]
[CONTACTS RE: HOUSE BILLS ONLY]
Brian Toohey None
Nicolas Magallanes Senior Advisor - House Republican Conference 2014-2105; Policy Advisor/Professional Staff Member - Rep. Lee Terry/Energy & Commerce Committee; 2012-2014; Legislative Correspondent/Legislative Aide - Sen. Lamar Alexander - 2010-2012
Nicholas Magallanes n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 22.
Original Filing: 301575683.xml
Lobbying Issues
General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General discussions related to Multi-Cancer Early Detection technology
HR 7085: BIOSECURE Act; all provisions
General Discussion related to funding for National Institutes of Health
General Discussion related to funding for Centers for Disease Control and Prevention
General Discussion related to funding for biosurveillance
General Discussions related to the implementation of P.L. 117-167 (HR 4346): Chips and Science Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to export control and trade policy
General Discussions related to biotechnology and genomics education
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
P.L. 118-31 (H.R. 2670): National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, ILLUMINA, INC. had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301540330.xml
Lobbying Issues
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness
H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding
General Discussions related to the Food and Drug Administration's regulation of diagnostics and lab developed test
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General Discussions related to the Cancer Moonshot Initiative
General Discussions related to genomic surveillance and pandemic preparedness
General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to export control and trade policy
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, ILLUMINA, INC. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301516441.xml
Lobbying Issues
H.R. 4420: Preparedness and Response Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness
H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act; provisions related to genomic surveillance and pandemic preparedness
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding
General Discussions related to the Food and Drug Administration's regulation of diagnostics
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General Discussions related to the Cancer Moonshot Initiative
General Discussions related to genomic surveillance and pandemic preparedness
General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to export control and trade policy
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, ILLUMINA, INC. had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301492290.xml
Lobbying Issues
H.R. 4420: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Protection, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness
H.R. 4421: To reauthorize certain programs under the Public Health Service Act with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response, and for other purposes.; provisions related to pandemic surveillance and national pandemic preparedness
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding
General Discussions related to the Food and Drug Administration's regulation of diagnostics
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General Discussions related to the Cancer Moonshot Initiative
General Discussions related to genomic surveillance and pandemic preparedness
General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to export control and trade policy
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024; provisions related to national security and trade
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301467374.xml
Lobbying Issues
Public Law No: 117-328 (H.R. 2617-117th Congress): Consolidated Appropriations Act, 2023; General Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, Centers for Disease Control and Prevention surveillance funding and National Institutes of Health funding
General Discussions related to the Food and Drug Administration's regulation of diagnostics
General Discussion related to Medicares payment system for clinical diagnostic laboratory services
General Discussions related to the Cancer Moonshot Initiative
General Discussions related to genomic surveillance and pandemic preparedness
General Discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General Discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Public Law No: 117-167 (H.R. 4346- 177th Congress): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); All provisions
General Discussions related to export control and trade policy
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, ILLUMINA, INC. had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301443329.xml
Lobbying Issues
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions
H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement
H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions
S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Public Law No: 117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
General discussions related to genomic surveillance and pandemic preparedness
General discussions related to the Cancer Moonshot Initiative
General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions
S. 1260: United States Innovation and Competition Act of 2021; all provisions
Public Law No: 117-167 (H.R. 4346): Supreme Court Security Funding Act of 2022 (f.k.a: The CHIPS and Science Act of 2022); all provisions
Public Law No: 117-328 (H.R. 2617): Consolidated Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, ILLUMINA, INC. had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301419171.xml
Lobbying Issues
H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions
H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement
H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions
S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
General discussions related to genomic surveillance and pandemic preparedness
General discussions related to the Cancer Moonshot Initiative
General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions
S. 1260: United States Innovation and Competition Act of 2021; all provisions
H.R. 4346: The CHIPS and Science Act of 2022; all provisions
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, ILLUMINA, INC. had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301395382.xml
Lobbying Issues
H.R. 6000: Cures 2.0 Act; all provisions
S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions
S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions
S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
General discussions related to genomic surveillance and pandemic preparedness
General discussions related to the Cancer Moonshot Initiative
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4521: United States Innovation and Competition Act of 2021; all provisions
S. 1260: United States Innovation and Competition Act of 2021; all provisions
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301371600.xml
Lobbying Issues
H.R. 6000: Cures 2.0 Act; all provisions
S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions
S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions
General discussions related to genomics, sequencing and applications for sequencing technologies
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
ILLUMINA, INC. filed a lobbying registration on Jan. 5, 2022 for in-house lobbying efforts, effective Jan. 1, 2022.
Original Filing: 301320182.xml
Issue(s) they said they’d lobby about: Legislation and regulations affecting sequencing and array-based solutions for genetic research, clinical and applied markets. .
1st Quarter, 2021
ILLUMINA, INC. in-house lobbying effort was terminated on April 20, 2021
Original Filing: 301266283.xml
Lobbying Issues
HR 1319: AMERICAN RESCUE PLAN ACT OF 2021; PROVISIONS RELATED TO GENOMIC SURVEILLANCE
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
(NO BILL #) - ENDING THE DIAGNOSTIC ODYSSEY ACT (fka: HR 4144 & S 3116 - 116TH CONGRESS); ALL PROVISIONS OF THE ACT
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
DISCUSSIONS RELATED TO THE MILLION VETERANS PROGRAM (MVP) - ISSUES RELATED TO PRECISION MEDICINE
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, ILLUMINA, INC. had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301245057.xml
Lobbying Issues
P.L. No: 116-139 (H.R. 266): PAYCHECK PROTECTION PROGRAM AND HEALTH CARE ENHANCEMENT ACT; PROVISIONS RELATED TO SURVEILLANCE FUNDING
P.L. No: 116-136 (H.R. 748): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION SURVEILLANCE FUNDING
H.R. 133 (P.L. 116-260): CONSOLIDATED APPROPRIATIONS ACT, 2021; PROVISIONS RELATED TO SURVEILLANCE FUNDING
H.R. 925: THE HEROES ACT; ; PROVISIONS RELATED TO SURVEILLANCE FUNDING
H.R. 6800: HEALTH AND ECONOMIC RECOVERY OMNIBUS EMERGENCY SOLUTIONS (HEROES) ACT; PROVISIONS RELATED TO SURVEILLANCE FUNDING
DISCUSSIONS RELATED TO CURES 2.0 DISCUSSION DRAFT; PROVISIONS RELATED TO GENOMIC TESTING
DISCUSSIONS RELATED TO GENOMICS, SEQUENCING AND THE APPLICATIONS FOR SEQUENCING INCLUDING IN RARE DISEASE, GENOMIC SURVEILLANCE, AND RELATED REIMBURSEMENT
DISCUSSIONS RELATED TO CENTERS FOR DISEASE CONTROL SURVEILLANCE FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
DISCUSSIONS RELATED TO THE MILLION VETERANS PROGRAM (MVP) - ISSUES RELATED TO PRECISION MEDICINE
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, ILLUMINA, INC. had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301223469.xml
Lobbying Issues
P.L. No: 116-139 (H.R. 266): PAYCHECK PROTECTION PROGRAM AND HEALTH CARE ENHANCEMENT ACT; PROVISIONS RELATED TO SURVEILLANCE FUNDING
P.L. No: 116-136 (H.R. 748): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION SURVEILLANCE FUNDING
H.R. 6800: HEALTH AND ECONOMIC RECOVERY OMNIBUS EMERGENCY SOLUTIONS (HEROES) ACT; PROVISIONS RELATED TO SURVEILLANCE FUNDING
H.R. 8337: CONTINUING APPROPRIATIONS ACT, 2021 AND OTHER EXTENSIONS ACT: PROVISIONS RELATED TO SURVEILLANCE FUNDING AND NATIONAL INSTITUTES OF HEALTH FUNDING
DISCUSSIONS RELATED TO CURES 2.0 DISCUSSION DRAFT; PROVISIONS RELATED TO GENOMIC TESTING
DISCUSSIONS RELATED TO HEALTHCARE DATA; ISSUES RELATED TO CONSUMER PRIVACY AND DATA SECURITY
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, ILLUMINA, INC. had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301200416.xml
Lobbying Issues
H.R. 266: PAYCHECK PROTECTION PROGRAM AND HEALTH CARE ENHANCEMENT ACT; PROVISIONS RELATED TO TESTING AND SURVEILLANCE
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION SURVEILLANCE FUNDING
H.R. 6800: HEALTH AND ECONOMIC RECOVERY OMNIBUS EMERGENCY SOLUTIONS (HEROES) ACT; PROVISIONS RELATED TO TESTING AND SURVEILLANCE
DISCUSSIONS RELATED TO HEALTHCARE DATA - ISSUES RELATED TO CONSUMER PRIVACY AND DATA SECURITY
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
ILLUMINA, INC. amended a lobbying report for in-house lobbying in Q12020 on April 20, 2020
Original Filing: 301179220.xml
Lobbying Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301179000.xml
Lobbying Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, ILLUMINA, INC. had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301127936.xml
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, ILLUMINA, INC. had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301078283.xml
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; PROVISIONS RELATED TO MAKING WHOLE GENOME SEQUENCING MORE ACCESSIBLE AS A DIAGNOSTIC
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, ILLUMINA, INC. had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301058217.xml
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO GENOMICS, SEQUENCING AND THE APPLICATIONS FOR SEQUENCING INCLUDING IN RARE DISEASE AND RELATED REIMBURSEMENT
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301037485.xml
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO GENOMICS, SEQUENCING AND THE APPLICATIONS FOR SEQUENCING INCLUDING IN RARE DISEASE AND RELATED REIMBURSEMENT
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, ILLUMINA, INC. had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301014364.xml
Lobbying Issues
H.R.5062: Advancing Access to Precision Medicine Act; All provisions of the bill
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, ILLUMINA, INC. had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300996428.xml
Lobbying Issues
H.R.5062: Advancing Access to Precision Medicine Act; All provisions of the bill
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, ILLUMINA, INC. had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300978461.xml
Lobbying Issues
H.R.5062: Advancing Access to Precision Medicine Act; All provisions of the bill
General discussions related to access to precision medicine
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, ILLUMINA, INC. had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300955170.xml
Lobbying Issues
GENERAL DISCUSSIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 5062: ADVANCING ACCESS TO PRECISION MEDICINE ACT; ALL PROVISIONS OF THE BILL
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
ILLUMINA, INC. filed a lobbying registration on April 4, 2018 for in-house lobbying efforts, effective Jan. 1, 2018.
Original Filing: 300942504.xml
Issue(s) they said they’d lobby about: Legislation and regulations affecting sequencing and array-based solutions for genetic research, clinical and applied markets. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...